
Sign up to save your podcasts
Or


The RENOVE trial compared reduced-dose versus full-dose DOACs for extended venous thromboembolism VTE treatment in high-risk patients.
While the reduced dose cut major bleeding risk by 39% 🚨, it did not meet non-inferiority criteria for preventing VTE recurrence 🔄.
By Dr RR Baliga, MD, MBA5
66 ratings
The RENOVE trial compared reduced-dose versus full-dose DOACs for extended venous thromboembolism VTE treatment in high-risk patients.
While the reduced dose cut major bleeding risk by 39% 🚨, it did not meet non-inferiority criteria for preventing VTE recurrence 🔄.

895 Listeners

3,360 Listeners

19,524 Listeners